New stem cell transplant approach shows promise for blood cancer patients without full matches
NCT ID NCT03480360
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemotherapy, radiation, and drugs to prevent rejection and graft-versus-host disease. The study tracked survival, engraftment, and immune recovery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- stem cell transplant with chemotherapy and radiation
- What this could lead to
- If successful, this approach could offer a safer, more accessible transplant option for people with blood cancers who lack a fully matched donor.
- What could go wrong
- This is a small, single-center trial with only 21 participants. The transplant carries serious risks, including graft-versus-host disease, infection, and organ damage. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
21 people
The number who actually took part.
- Started
-
Mar 2018
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: less than 75 years * The patient must be approved for transplant by the treating transplant physician. This includes completion of their pre-transplant workup, as directed by standard Dartmouth-Hitchcock Medical Center (DHMC) Standard Operating Procedure (SOP) (DHMC SOP - Pre-transplant Evaluation of allogeneic recipient (Appendix). * The patient must have a disease (listed below) with treatment-responsiveness that the treating transplant physician believes will benefit from an allogeneic stem cell transplant. The diseases include: * Acute leukemia - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia * Chronic leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia * Myelodysplasia * Myeloproliferative disorder * Myelofibrosis * Lymphoma - Non-Hodgkin's Lymphoma or Hodgkin's disease * Plasma cell disorder, including myeloma, Waldenstrom's Macroglobulinemia * Donor availability- the patient must have an identified RELATED haplo-identical donor * No Human Immunodeficiency Virus infection or active hepatitis B or C * Eastern Cooperative Oncology Group performance status: 0-2 * Diffusing capacity of carbon monoxide (DLCO) greater than or equal to 40 % predicted * Left ventricular ejection fraction greater than or equal to 40% * Serum bilirubin \< 2x upper limit of normal; transaminases \< 3x normal at the time of transplant * No active or uncontrollable infection * In female, a negative pregnancy test if experiencing menstrual periods * No major organ dysfunction precluding transplantation * No evidence of an active malignancy that would limit the patient's survival to less than 2 years. (If there is any question, the PI can make a decision). Exclusion Criteria: * Psychiatric disorder or a mental deficiency of the patient that is sufficiently severe to make compliance with the treatment unlikely, and making informed consent impossible. * Major anticipated illness or organ failure incompatible with survival from bone marrow transplant. * History of refractory systemic infection DONOR ELIGIBILITY * Human leukocyte antigen (HLA) haplo-identical matched related. * The donor must be healthy and must be willing to serve as a donor, based on standard National Marrow Donor Program (NMDP) guidelines and DHMC SOP - Donor Evaluation (Appendix) * The donor must have no significant co-morbidities that would put the donor at marked increased risk * There is no age restriction for the donor * Informed consent must be signed by donor DONOR EXCLUSION CRITERIA * The NMDP guidelines for exclusion criteria will be used (Appendix). In addition, the following donors are NOT eligible: * Pregnant or lactating donor * HIV or active Hep B or C in the donor * Donor unfit to receive G-CSF and undergo apheresis * A donor with a psychiatric disorder or mental deficiency that makes compliance with the procedure unlikely and informed consent impossible
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphocytic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bispecific antibody combo aims to deepen myeloma responses
- Can a stronger drug cocktail give older myeloma patients a better start?
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Can a p53-Targeting drug boost chemotherapy in Hard-to-Treat blood cancers?